Evidence map›Paper›PMID 33742316›Full record

ArticleInternational urology and nephrology2021

Outcomes of a single trigone-only vs. 20 trigone-sparing injections of OnabotulinumtoxinA for refractory overactive bladder (OAB).

Jessica Ton, Perrin Downing, Eboo Versi, Stefanie van Uem, Sonya Ephraim, Miles Murphy, Vincent Lucente

Registry-linked trialAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05308979 (Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05308979 phase4completednot on this mapstarted 2022, after this paper: background citation

Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

TypeinterventionalSponsorUniversity of California, IrvineRan2022 to 2024Enrolled116ConditionsOveractive Bladder, Urinary Urge Incontinence, Overactive Bladder Syndrome, Urinary Incontinence, UrgeArmsOnabotulinumtoxinA 100 UNT [Botox]
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Jessica TonAnne Arundel Medical Center, Annapolis, MD, USA.
Perrin DowningAbington Hospital-Jefferson Health, Abington, PA, USA.
Eboo VersiRutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. ebooversi@gmail.com.ORCID http://orcid.org/0000-0001-9366-7370
Stefanie van UemDepartment of Urology, Stanford University School of Medicine, San Francisco, USA.
Sonya EphraimMercyhealth System, Rockford, IL, USA.
Miles MurphyInstitute for Female Pelvic Medicine, Allentown, PA, USA.
Vincent LucenteInstitute for Female Pelvic Medicine, Allentown, PA, USA.
Institute for Female Pelvic Medicine and Reconstructive Surgery · USAbington Memorial Hospital · USAnne Arundel Medical Center · USMercy Health System · USRutgers, The State University of New Jersey · USStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare the safety and durability of a single intravesical trigonal-only versus 20 trigone-sparing injections of OnabotulinumtoxinA (BTA) for refractory OAB.

methodsA chart review of all idiopathic OAB patients treated with BTA from January 2016 to December 2018 was performed. Outcomes measures included: inter-injection interval, post-void residual (PVR), urinary tract infections (UTI), urinary retention requiring catheterization, and procedure time (min). Statistical analyses were performed using independent sample t-tests.

resultsBaseline characteristics were comparable for the two groups, data on 69 treatments (19 patients trigone-only) were compared to 105 treatments (26 patients trigone-sparing). There were no differences in the inter-injection intervals or rates of UTI. The trigone-only group exhibited a lower mean PVR (113 ml vs 160 ml, p < 0.02), lower proportion with PVR > 150 ml (23% vs. 39%, p < 0.03), lower rate of urinary retention (5.3% vs. 17.4%, p < 0.02), and shorter procedure time (4.3 min vs. 5.7 min, p < 0.01). There were no cases of vesico-ureteral reflux.

conclusionWhile interpretation remains speculative, the results of this observational study suggest that a single trigone-only injection appears to be as safe and durable as multiple trigone-sparing injections but maybe quicker to perform and appears to have a lower impact on voiding function. Larger series and adequately powered prospective randomized clinical trials are warranted to validate the findings of this pilot study.

Indexed as

Administration, IntravesicalAgedAged, 80 and overBotulinum Toxins, Type AFemaleHumansMiddle AgedPilot ProjectsRetrospective StudiesTreatment OutcomeUrinary BladderUrinary Bladder, OveractiveBotulinum Toxins, Type Aonabotulinum toxin ABTAOABOnabotulinumtoxinAOveractive bladderTrigone-onlyTrigone-sparing

Identifiers

PMID33742316
OpenAlexW3139239908

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.